Physician in the Loop: Oncology https://physicianintheloop.org/specialties/oncology/ Transistor (https://transistor.fm) https://feeds.transistor.fm/physician-in-the-loop-oncology The week's innovation news in oncology for oncologists, every Sunday in a few minutes: new technology, AI tools, devices, FDA decisions and new ways of delivering care. From the Specialties pages of Physician in the Loop, where every story links to its sources: physicianintheloop.org/specialties/oncology/. Read by AI voices. Nomad Medical Group, PLLC f20e373a-0d3a-5cd4-b7ab-ccdc4da48b3e yes en Sun, 08 Nov 2026 12:52:05 -0700 Sun, 08 Nov 2026 12:52:20 -0700 https://img.transistorcdn.com/8OWMj_hcFftilabQPMr_Kie5cY3qxAS68Al0zS4TQWE/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS85YzQ3/ZTYwNDBlYTI1ODA0/ZDhiMzU3YjI5YmUx/OTljZS5qcGc.jpg Physician in the Loop: Oncology https://physicianintheloop.org/specialties/oncology/ episodic Nomad Medical The week's innovation news in oncology for oncologists, every Sunday in a few minutes: new technology, AI tools, devices, FDA decisions and new ways of delivering care. From the Specialties pages of Physician in the Loop, where every story links to its sources: physicianintheloop.org/specialties/oncology/. Read by AI voices. The week's innovation news in oncology for oncologists, every Sunday in a few minutes: new technology, AI tools, devices, FDA decisions and new ways of delivering care. oncology, oncology news, innovation, medicine, physicians, AI in medicine, weekly briefing Ryan Gillum No No Weekly Briefing for November 1 to 7, 2026 5 5 Weekly Briefing for November 1 to 7, 2026 full ed26c872-4562-423e-a99f-041817971abe https://share.transistor.fm/s/7ababa27 The Food and Drug Administration (FDA) granted accelerated approval on Nov. 5 to subcutaneous amivantamab for previously treated recurrent or metastatic head and neck squamous cell carcinoma. The Centers for Medicare & Medicaid Services (CMS) issued the 2027 physician fee schedule final rule, cutting the main conversion factor 2.31%.

Read this week's roundup and its sources: https://physicianintheloop.org/specialties/oncology/2026-11-01/

Get this roundup by email, free

The voices on this episode are generated by AI, and so is the script, from the week's specialty roundup at Physician in the Loop. Every fact in the roundup links to its source.

]]> The Food and Drug Administration (FDA) granted accelerated approval on Nov. 5 to subcutaneous amivantamab for previously treated recurrent or metastatic head and neck squamous cell carcinoma. The Centers for Medicare & Medicaid Services (CMS) issued the 2027 physician fee schedule final rule, cutting the main conversion factor 2.31%.

Read this week's roundup and its sources: https://physicianintheloop.org/specialties/oncology/2026-11-01/

Get this roundup by email, free

The voices on this episode are generated by AI, and so is the script, from the week's specialty roundup at Physician in the Loop. Every fact in the roundup links to its source.

]]> Sun, 08 Nov 2026 12:52:05 -0700 Nomad Medical Nomad Medical 135 FDA grants subcutaneous amivantamab accelerated approval in head and neck cancer; final 2027 Medicare fee schedule cuts conversion factor 2.31% FDA grants subcutaneous amivantamab accelerated approval in head and neck cancer; final 2027 Medicare fee schedule cuts conversion factor 2.31% Oncology,physicians,innovation,AI in medicine,weekly briefing No Weekly Briefing for October 25 to 31, 2026 4 4 Weekly Briefing for October 25 to 31, 2026 full 06df9d25-5452-448d-ad92-d0dea256aff8 https://share.transistor.fm/s/bc784f46 The Food and Drug Administration (FDA) on Oct. 26 approved talazoparib with enzalutamide for metastatic androgen pathway modulation-naive or -sensitive prostate cancer with homologous recombination repair gene mutations.

At the European Society for Medical Oncology (ESMO) Congress, divarasib extended progression-free survival over sotorasib or adagrasib, and Genmab said petosemtamab plus pembrolizumab improved overall survival in head and neck cancer. The American Society for Radiation Oncology (ASTRO) backed moderate hypofractionation in prostate cancer.

Read this week's roundup and its sources: https://physicianintheloop.org/specialties/oncology/2026-10-25/

Get this roundup by email, free

The voices on this episode are generated by AI, and so is the script, from the week's specialty roundup at Physician in the Loop. Every fact in the roundup links to its source.

]]> The Food and Drug Administration (FDA) on Oct. 26 approved talazoparib with enzalutamide for metastatic androgen pathway modulation-naive or -sensitive prostate cancer with homologous recombination repair gene mutations.

At the European Society for Medical Oncology (ESMO) Congress, divarasib extended progression-free survival over sotorasib or adagrasib, and Genmab said petosemtamab plus pembrolizumab improved overall survival in head and neck cancer. The American Society for Radiation Oncology (ASTRO) backed moderate hypofractionation in prostate cancer.

Read this week's roundup and its sources: https://physicianintheloop.org/specialties/oncology/2026-10-25/

Get this roundup by email, free

The voices on this episode are generated by AI, and so is the script, from the week's specialty roundup at Physician in the Loop. Every fact in the roundup links to its source.

]]> Sun, 01 Nov 2026 04:21:19 -0700 Nomad Medical Nomad Medical 326 FDA approves talazoparib with enzalutamide for HRR-mutated prostate cancer; divarasib beats KRAS G12C inhibitors; petosemtamab improves survival FDA approves talazoparib with enzalutamide for HRR-mutated prostate cancer; divarasib beats KRAS G12C inhibitors; petosemtamab improves survival Oncology,physicians,innovation,AI in medicine,weekly briefing No Weekly Briefing for October 11 to 17, 2026 3 3 Weekly Briefing for October 11 to 17, 2026 full 83136995-641a-4f7b-bfbe-3d28cd33505b https://share.transistor.fm/s/feb72e9c The Food and Drug Administration (FDA) cleared SimBioSys's TumorSight Risk, AI software that combines breast MRI, pathology and clinical data to score breast cancer recurrence risk, the company said Oct. 15.

In other developments, 19.8% of 958 clinicians used an ambient AI scribe in a JCO Oncology Practice study, an AI nutrition platform met equivalence with dietitians, and digital outreach reached 11% of patients invited to check lung screening eligibility.

Read this week's roundup and its sources: https://physicianintheloop.org/specialties/oncology/2026-10-11/

Get this roundup by email, free

The voices on this episode are generated by AI, and so is the script, from the week's specialty roundup at Physician in the Loop. Every fact in the roundup links to its source.

]]> The Food and Drug Administration (FDA) cleared SimBioSys's TumorSight Risk, AI software that combines breast MRI, pathology and clinical data to score breast cancer recurrence risk, the company said Oct. 15.

In other developments, 19.8% of 958 clinicians used an ambient AI scribe in a JCO Oncology Practice study, an AI nutrition platform met equivalence with dietitians, and digital outreach reached 11% of patients invited to check lung screening eligibility.

Read this week's roundup and its sources: https://physicianintheloop.org/specialties/oncology/2026-10-11/

Get this roundup by email, free

The voices on this episode are generated by AI, and so is the script, from the week's specialty roundup at Physician in the Loop. Every fact in the roundup links to its source.

]]> Sun, 18 Oct 2026 03:55:31 -0600 Nomad Medical Nomad Medical 214 FDA clears MRI-based AI breast cancer recurrence tool; ambient AI scribe sees low uptake in oncology; AI nutrition platform matches dietitians FDA clears MRI-based AI breast cancer recurrence tool; ambient AI scribe sees low uptake in oncology; AI nutrition platform matches dietitians Oncology,physicians,innovation,AI in medicine,weekly briefing No Weekly Briefing for October 5 to 11, 2026 2 2 Weekly Briefing for October 5 to 11, 2026 full d9b37147-2470-4180-8c08-787e9efb09a7 https://share.transistor.fm/s/a0e100a1 Readmission within 30 days was 30% with a digital transitional care program versus 37% with usual care for patients with cancer at Memorial Sloan Kettering, an npj Digital Medicine study found. Natera said the Food and Drug Administration (FDA) granted its multi-cancer early detection assay breakthrough device designation, and Telix said the first patients received its glioma PET agent Pixclara.

Read this week's roundup and its sources: https://physicianintheloop.org/specialties/oncology/2026-10-05/

Get this roundup by email, free

The voices on this episode are generated by AI, and so is the script, from the week's specialty roundup at Physician in the Loop. Every fact in the roundup links to its source.

]]> Readmission within 30 days was 30% with a digital transitional care program versus 37% with usual care for patients with cancer at Memorial Sloan Kettering, an npj Digital Medicine study found. Natera said the Food and Drug Administration (FDA) granted its multi-cancer early detection assay breakthrough device designation, and Telix said the first patients received its glioma PET agent Pixclara.

Read this week's roundup and its sources: https://physicianintheloop.org/specialties/oncology/2026-10-05/

Get this roundup by email, free

The voices on this episode are generated by AI, and so is the script, from the week's specialty roundup at Physician in the Loop. Every fact in the roundup links to its source.

]]> Mon, 12 Oct 2026 03:48:54 -0600 Nomad Medical Nomad Medical 165 Digital follow-up lowers cancer readmissions; FDA names Natera MCED test a breakthrough device; first patients get Pixclara PET Digital follow-up lowers cancer readmissions; FDA names Natera MCED test a breakthrough device; first patients get Pixclara PET Oncology,physicians,medical news,weekly briefing No Weekly Briefing for September 28 to October 4, 2026 1 1 Weekly Briefing for September 28 to October 4, 2026 full 17d4c1e9-c592-4252-8756-857615d387ef https://share.transistor.fm/s/51201fcd The Food and Drug Administration (FDA) on Oct. 2 approved Eli Lilly's pirtobrutinib for adults with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma with no known 17p deletion.

A phase 3 trial published Sept. 28 in the Journal of Clinical Oncology found radiation tiles placed during brain metastasis surgery cut surgical bed recurrence. At the American Society for Radiation Oncology meeting, protons did not improve survival over photons in liver cancer. Bayer said the FDA granted priority review to elinzanetant for hot flashes during breast cancer endocrine therapy.

Read this week's roundup and its sources: https://physicianintheloop.org/specialties/oncology/2026-09-28/

The voices on this episode are generated by AI, and so is the script, from the week's specialty roundup at Physician in the Loop. Every fact in the roundup links to its source.

]]> The Food and Drug Administration (FDA) on Oct. 2 approved Eli Lilly's pirtobrutinib for adults with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma with no known 17p deletion.

A phase 3 trial published Sept. 28 in the Journal of Clinical Oncology found radiation tiles placed during brain metastasis surgery cut surgical bed recurrence. At the American Society for Radiation Oncology meeting, protons did not improve survival over photons in liver cancer. Bayer said the FDA granted priority review to elinzanetant for hot flashes during breast cancer endocrine therapy.

Read this week's roundup and its sources: https://physicianintheloop.org/specialties/oncology/2026-09-28/

The voices on this episode are generated by AI, and so is the script, from the week's specialty roundup at Physician in the Loop. Every fact in the roundup links to its source.

]]> Mon, 05 Oct 2026 22:05:06 -0600 Nomad Medical Nomad Medical 274 FDA approves pirtobrutinib for untreated CLL; tiles cut brain metastasis recurrence; protons fail to extend liver cancer survival FDA approves pirtobrutinib for untreated CLL; tiles cut brain metastasis recurrence; protons fail to extend liver cancer survival Oncology,physicians,medical news,weekly briefing No